• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Syngene

    test company saurabh

    Emergent BioSolutions

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Reed-Lane

    test company saurabh

    Aphena Pharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Continued and Consistent Investment in Manufacturing Facilities

    As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge

    Related CONTENT
    • Century Therapeutics Significantly Expands Capabilities
    • FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    • Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
    • Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    • RheinCell Therapeutics Achieves GMP Certification
    Ryan Carpentier, Executive Director of Business Development, Cryoport09.23.19
    What are the driving factors behind the investments in new and expanded manufacturing capabilities in the cell and gene therapy sector?  Firstly, there is an acute shortage in existing manufacturing capacity in the cell and gene therapy development process with access for new programs at times exceeding eight months.  The current shortage has companies appreciating that manufacturing readiness needs to be at the forefront of the clinical and commercialization strategy.  We’ve already seen some companies delay commercial launches because of the lack of manufacturing capacity. Manufacturing capacity to support Phase I trials with small patient populations typically isn’t an issue.  However, as hundreds of companies move their cell and gene therapies through the development process, supporting larger patient populations in Phase III trials and commercial launches will be a challenge. 

    The US FDA predicts it will receive more than 200 regenerative INDs per year by 2020. The FDA also predicts that they will be approving 10 to 20 cell and gene therapies a year by 2025, based on an assessment of the current pipeline and the clinical success rates of these products. To cope with this demand, the FDA is hiring an additional 50 clinical reviewers dedicated to these revolutionary products.1 “The activity reflects a turning point in the development of these technologies and their application to human health,” former FDA Commissioner Gottlieb’s statement read. “It’s similar to the period marking an acceleration in the development of antibody drugs in the late 1990s, and the mainstreaming of monoclonal antibodies as the backbone of modern treatment regimens.”

    There have been two predominant themes at this years’ trade shows, workshops, and at the CEO roundtables. The first theme can be summed up in this quote from Joanne Beck, Celgene Executive Vice President for Global Pharmaceutical Development: “It came as a surprise that manufacturing could play such an important role in a therapy.” In addition, many of these executives are seeing the opposite of traditional drug development, where the regulatory body spends 80% of the review focused on the clinical data and 20% on manufacturing. In the cell and gene therapy space these numbers are often inverted with 80% of the review focused on manufacturing.  The regulatory review for regenerative therapies is largely going to be focused on manufacturing and operational capabilities.

    Former FDA Commissioner Scott Gottlieb noted: “One example is how we’re considering innovative trial designs whereby individual academic investigators would follow the same manufacturing protocols and share combined clinical trial data in support of approval from the FDA. This is an innovative way of making sure that small investigators who are working with cells that are being manufactured in ways that render them subject to our current laws and regulations—because the cells are, for example, more than ‘minimally manipulated’—can nonetheless seek the FDA’s approval through a less burdensome process.”   In fact, bringing manufacturing capabilities in house for later stage development is seen as a competitive advantage to some.  All too often, we’ve seen companies that have great success in an academic setting try and bring therapies to market, only to realize that they don’t have the capacity to keep up with larger demand.  In addition to pharma and biotech companies expanding their own capabilities, it’s no surprise that contract manufacturing companies, like Lonza, have made a substantial investment in their cell and gene therapy manufacturing capabilities.  In fact, last year Lonza committed to build a 300,000-square-foot location in Houston, which will be the largest dedicated cell and gene therapy manufacturing facility in the world.

    The second theme revolves around the fact that the “process is the product”.  The process of manufacturing Autologous or Allogeneic therapies is complex and expensive.  For starters, the manufacturing facility must maintain GMP accreditation, which in and of itself is not easy.  Secondly, there is great variability between patients; lots; and, raw materials.  We constantly hear CEO’s talking about the need to scale out (adding new resources), not scale up (increasing capacity of existing resources).  The products companies are dealing with are living and change with each patient.  Moving apheresis products from the clinic to the manufacturing facility must be done quickly, efficiently, and with minimal risk.  Companies must understand the impact of moving these products at different temperature bands to ensure they arrive at their destination in the desired and required condition. 

    The process for autologous therapies is incredibly complex due to the variability of the individual patient.  Trying to scale (leukapheresis; selection and activation; gene transfer; cell expansion; and, infusion) is difficult.  In many cases, the patient is extremely ill and the manufacturer has a limited number of chances to get it right.  They can’t afford to have a breakdown in the supply chain.  There is no room for failure.  The supply chain stake holders need to lead, or at least have a strong voice, regarding process design and standardization of the space.  We also know regulatory bodies and industry organizations are framing new guidelines governing the distribution of temperature-sensitive materials. Guidelines relating specifically to the cold chain are in place in Argentina, Australia, Austria, Bahrain, Brazil, Canada, China, The Czech Republic, Egypt, the EU, India, Ireland, Italy, Jordan, Mexico, Romania, Singapore, Saudi Arabia, South Africa, South Korea, the United Arab Emirates, the United States, Syria and Venezuela.  The Food & Drug Administration, the Parental Drug Association, the U.S. Pharmacopeia, the International Air Transportation Association and other organizations also have established guidelines for the transportation of temperature sensitive products. 

    Today there are more than 800 active IND’s on file with the FDA and we’re just starting to see development of therapies targeting solid tumors.  Will today’s manufacturing capacity be able to keep up with the speed at which these products are being driven through the development process?  Today the answer is no.  However, the industry has started to adjust by making significant investments in brand new facilities or large expansions of existing locations.

    There are several examples of manufacturing expansion, among them are: 
    Pfizer recently announced that they will be investing an additional $500 million and adding 300 more jobs to increase manufacturing capability at their newly completed gene therapy plant on a 230-acre campus in Sanford, NC. The expansion comes only two years after the pharmaceutical company started a separate $100 million expansion of a gene therapy manufacturing facility that added 40 jobs to what is now a 650-person workforce.2

    Additionally, Precision BioSciences opened their first in-house cGMP manufacturing facility dedicated to genome-edited allogeneic CAR T-cell therapies in the United States.  They believe that the facility also has the potential to be a commercial launch facility with the capacity to generate up to 10,000 doses of CAR T-cell therapies and 4,000 doses of gene therapies per year.3

    Precigen, Inc., a wholly owned subsidiary of Intrexon Corp. and a clinical stage biopharmaceutical company, announced the official opening of their new manufacturing facility recently. Precigen started the build-out of the nearly 5,000-square-foot manufacturing facility in 2018.  The new facility adds to Precigen's existing facility in Germantown, MD.4   

    Another example of manufacturing expansion is from Iovance Biotherapeutics, a late-stage biotechnology company developing cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. They announced the plan to build an approximately 136,000-square-foot commercial-scale production facility in Philadelphia for production of their leading therapy lifileucel.5

    Kite, a Gilead Company, announced plans for a new facility in Frederick County, MD, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta®(axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors.6

    Finally, bluebird bio opened their first wholly owned manufacturing facility to produce lentiviral vectors for their investigational gene and cell therapies.  The 125,000-square-foot facility currently employees 50 scientists, engineers, manufacturing and operations personal but is estimated to grow to 70 employees by the end of 2019.7

    Additionally, contract manufacturing companies also have been expanding their footprints.  Some examples are:
     
    In 2017 Brammer Bio announced the completion of renovations and the launch of their late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, MA for gene therapy products.8
     
    In Europe, MaSTherCell S.A., signed a lease for a 61,000-square-foot plant in Belgium that will be built into a manufacturing site for late-stage and commercially approved cell and gene therapy products.9
     
    PTC Therapeutics signed a long-term lease agreement with Bristol-Myers Squibb (BMS) to gain access to approximately 185,000 square feet of space, including an existing state-of-the-art biologics production facility and supporting research and operations buildings on the BMS Hopewell, NJ campus. PTC plans to further develop the biologics facility to support future gene therapy production.10
     
    The biggest takeaway from all of the above manufacturing expansion?  That the daily drum beat of companies expanding or creating their own manufacturing capabilities is growing louder and will continue for the foreseeable future as the number of clinical trials keeps increasing and as new therapies are commercially approved.  Companies that have the capacity to meet demand and are able to mitigate manufacturing risk will not only have a competitive edge, they’ll be delivering lifesaving therapies in predictable and consistent manner to meet the needs of patients.
     
     
    References:
    1.     https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics. 
    2.     https://businessfacilities.com/2019/08/pfizer-investing-additional-500m-sanford-north-carolina/
    3.     https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-opens-first-house-cgmp-manufacturing
    4.     https://finance.yahoo.com/news/precigen-opens-gene-cell-therapy-200500012.html
    5.     https://www.globenewswire.com/news-release/2019/05/29/1856278/0/en/Iovance-Biotherapeutics-Announces-New-Facility-to-Support-U-S-Production-of-Tumor-Infiltrating-Lymphocyte-Cell-Therapy-Products.html
    6.     https://www.businesswire.com/news/home/20190424005257/en/
    7.     https://www.biopharma-reporter.com/Article/2019/04/10/Bluebird-ramps-up-lentiviral-vector-production-with-Durham-Facility
    8.     https://www.prnewswire.com/news-releases/brammer-bio-launches-gene-therapy-product-manufacturing-operations-in-massachusetts-300561571.html
    9.     https://www.biopharmadive.com/news/masthercell-to-build-cell-and-gene-therapy-plant-in-belgium/551322/
    10.  https://www.contractpharma.com/contents/view_breaking-news/2019-08-05/ptc-therapeutics-expands-in-new-jersey-by-securing-state-of-the-art-biologics-facility/




     
    Ryan Carpentier is Cryport's Global Operations, Sales, and Business Development executive with proven success in creating processes, leading international initiatives, and generating millions of dollars in revenue and profit growth. He combines expert strategic planning and business planning skills with consistent success in leading operations, developing strategies, and delivering strong financial results and profitable growth. He is a dedicated, inspirational, intelligent, and positive leader able to inspire trust, clarify purpose, attract top talent, build cross-functional teams, mitigate risk, and dramatically improve operational performance.
    Related Searches
    • pfizer
    • Manufacturing
    • immunotherapies
    • cGMP
    Suggested For You
    Century Therapeutics Significantly Expands Capabilities Century Therapeutics Significantly Expands Capabilities
    FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site FUJIFILM Diosynth Hosts UK PM at COVID Vax Mfg. Site
    Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine Novartis Inks Contract Manufacturing Deal for Pfizer-BioNTech COVID-19 Vaccine
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    RheinCell Therapeutics Achieves GMP Certification RheinCell Therapeutics Achieves GMP Certification
    Fujifilm to Invest $40M in New Facility Fujifilm to Invest $40M in New Facility
    Recipharm Expands API Manufacturing Capabilities Recipharm Expands API Manufacturing Capabilities
    Samsung Biologics Launches Virtual Showroom Samsung Biologics Launches Virtual Showroom
    BD to Invest $1.2B in Pre-Fillable Syringe Manufacturing Capacity BD to Invest $1.2B in Pre-Fillable Syringe Manufacturing Capacity
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    ApiJect Systems Approved for $590 Million Loan ApiJect Systems Approved for $590 Million Loan
    Baxter Invests $50M to Expand Sterile Fill/Finish Manufacturing Operations Baxter Invests $50M to Expand Sterile Fill/Finish Manufacturing Operations
    Cell & Gene Therapy Supply Chain: Early Preparation is Key Cell & Gene Therapy Supply Chain: Early Preparation is Key

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20

    • Biologics, Proteins, Vaccines | Cold Chain Management | Logistics | Supply Chain
      Rising to The Occasion: The High Stakes of Vaccine Transport

      Rising to The Occasion: The High Stakes of Vaccine Transport

      How logistical precision can ensure safe and efficient delivery of the COVID-19 vaccine.
      Bill Brooks, Vice President of North America Transportation Portfolio at Capgemini 11.04.20


    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20

    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20


    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20


    • Clinical Trials | Drug Development
      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Evaluating outsourcing strategies amid a complex trial landscape to further enhance clinical operations.
      Michael D. Jones , Vice President of Clinical FSP Client Engagement, IQVIA 08.17.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20

    • Drug Development | GMPs/GCPs | Information Technology | QA/QC
      Solving Compliance Challenges and Beyond with Natural Language Processing

      Solving Compliance Challenges and Beyond with Natural Language Processing

      Understanding new data sources and elevating compliance to drive innovation.
      Updesh Dosanjh, Practice Lead, IQVIA Vigilance Platform, IQVIA, Jane Reed, Head of Life Science Strategy, Linguamatics, an IQVIA company 06.16.20

    Trending
    • Century Therapeutics Significantly Expands Capabilities
    • Catalent Acquires Delphi Genetics
    • Sanofi And Translate Bio Expand Vaccine Collaboration
    • RotaChrom Technologies Partners With Cyclolab
    • Inside A Vaccine Trial
    Breaking News
    • Altasciences Contributes to Vibegron Approval
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Terumo to Purchase Predictive Analytics Firm Health Outcomes Sciences
    Abiomed Leader Michael Minogue Named AdvaMed Board Chairman
    TransEnterix Changes Name to Asensus Surgical
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Altasciences Contributes to Vibegron Approval
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Afro Sheen Launches New Brand Initiatives
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Implants for Use in Spinal Surgeries Become Available
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login